While androgen deprivation therapy (ADT) remains the mainstay of systemic treatment, the addition of AR signaling inhibitors (ARSIs) provides substantial improvement in overall survival and quality of life for many men with advanced prostate cancer [1,2,3,4,5,6,7]. The gene discussed is AR; the disease is prostate carcinoma.